Moleculin Biotech, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Moleculin Biotech, Inc. (MBRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $11.72 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-18
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.61.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $1.76, a 23.81% decline year-over-year.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $2.31.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $11.72, a 365.08% increase from fiscal 2024.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.52, a 72.00% decline from fiscal 2023.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $9.00, a 504.03% increase from fiscal 2022.
- Moleculin Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.49, a 60.16% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $11.72 10-K · filed 2026-03-18 | |||
| 2024-12-31 | $2.52 10-K · filed 2025-03-21 | |||
| 2023-12-31 | $9.00 10-K · filed 2024-03-22 | |||
| 2023-09-30 | $0.60 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $0.60 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $1.49 10-K · filed 2023-03-22 | |||
| 2022-09-30 | $1.49 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $1.49 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | $1.61 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $3.74 10-K · filed 2022-03-24 | |||
| 2021-09-30 | $3.75 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $3.75 10-Q · filed 2021-08-11 | |||
| 2020-12-31 | $5.66 10-K · filed 2021-03-24 | |||
| 2020-09-30 | $0.95 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $1.24 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $1.29 10-K · filed 2020-03-19 | |||
| 2019-09-30 | $1.30 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $1.15 10-Q · filed 2019-08-16 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | $1.79 10-K · filed 2019-02-21 | |||
| 2018-09-30 | $1.81 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $1.81 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | $1.76 10-Q · filed 2018-05-14 | |||
| 2017-12-31 | $2.42 10-K · filed 2018-03-28 | |||
| 2017-09-30 | $2.14 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $2.31 10-Q · filed 2017-08-11 | |||
| 2017-03-31 | $2.31 10-Q · filed 2017-05-12 | |||
| 2016-12-31 | $5.83 10-K · filed 2018-03-28 | |||
| 2016-09-30 | $5.83 10-Q · filed 2016-11-21 | |||
| 2015-12-31 | $0.20 10-K · filed 2017-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |